DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for gamma chain deficiency — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGamma chain deficiency maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gamma chain deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 2 receptor subunit gamma (IL2RG) — IL2RG is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cysdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5M5E · 2.3 Å · ligand CYSTEINE (CYS). Experimental structure, not a prediction.
What the evidence adds up to
Of the 59 patients with various immune deficiencies analysed in 1970, 13 had gammaG subgroup imbalances, all with non sex-linked disease. Eleven of those 13 showed a preponderance of the gammaG3 subgroup, and within that subgroup the Gm(b) type was selectively retained while the Gm(g) type was markedly depressed. Other imbalances included predominance of the gammaG2 subgroup and selective absence of single gammaG subgroups. One family had probable structural gene abnormalities in the autosomal Gm loci, with both parents carrying different abnormal gene complexes and the propositus inheriting both. In two other families with subgroup imbalance, structural gene defects could be excluded. Among 22 first-degree relatives of patients with subgroup imbalances, the most common abnormality was in gammaA, which was absent in three and markedly decreased in two others.
The 1962 paper describes three main forms of significant hypogammaglobulinemia: a transient prolongation of the normal gamma globulin depression between the second and fourth months of infancy; a congenital form, usually in boys, with sex-linked recessive inheritance; and an acquired primary form in both sexes at any age. The authors state that replacement therapy with pooled normal gamma globulin is effective in preventing serious infections if initiated before structural damage has occurred, but that supplies should not be wasted on patients whose susceptibility to infection has other causes, and that patients should not be subjected to repeated large intramuscular injections except on clear-cut indications.
A 1996 study of dapsone therapy for thrombocytopenia in HIV-infected patients compared intravenous gamma globulin and Rh antibodies in Rh-positive patients, finding both treatments well tolerated and neither superior to the other. The authors concluded that each treatment can be used after failure of the other. No data in these abstracts address any drug treatment specifically for gamma chain deficiency, nor do they report survival or response rates for any intervention in that disease. What is missing is any controlled trial of drug therapy for gamma chain deficiency itself, along with patient stratification by genetic subtype and funding for such a trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Clinical Investigation · 1970 · 138 citations · open access
Imbalances of gamma globulin subgroups and gene defects in patients with primary hypogammaglobulinemia
AbstractAnalysis of immunoglobulin classes, gammaG subgroups, and Gm genetic markers from 59 patients with various types of immune deficiencies was undertaken to assess the function of the several cistrons concerned with synthesis of gamma globulins. 13 patients including two sibling pairs were found to have gammaG subgroup imbalances. All of these patients had non sex-linked disease. 11 of the 13 had preponderance of the gammaG3 subgroup. In most instances of gammaG3 preponderance it was the Gm(b) type of gammaG3 that was selectively retained; the Gm(g) type, controlled by the allelic gene was markedly depressed but not absent in the cases where it could be studied. Other imbalances, either seen concomitantly with gammaG3 preponderance or independently, included predominance of the gammaG2 subgroup and selective absence of single gammaG subgroups.One family was encountered with probable structural gene abnormalities in the autosomal Gm loci. Both parents had different abnormal gene complexes detectable by absence of specific Gm markers and the propositus received both types from the parents. Similar gene complexes have been seen previously in rare instances through population screening but only in the heterozygous state and were not associated with clinically evident hypogammaglobulinemia. Of several other families of patients with subgroup imbalance, two were informative in that structural gene defects could be excluded. Studies on 22 first degree relatives of patients with subgroup imbalances indicated that the most common abnormality detected was in gammaA which was absent in 3 and markedly decreased in 2 others; other abnormalities included decreased levels of specific genetic types of gammaG globulin. It is concluded that gammaG subgroup imbalances are frequently found in non sex-linked immunoglobulin deficiency disorders and in some instances may be associated with family abnormalities suggesting either regulator or structural gene defects.
Dapsone Therapy for Thrombocytopenia in Patients Infected with Human Immunodeficiency Virus
AbstractIn a previous report, we compared the effectiveness of transfus ing intravenous gamma globulin and Rh antibodies into Rh-posi tive patients and found that both treatments were well tolerated [7]. Our data did not indicate that one form oftherapy was superior to the other. Nevertheless, individual responses may be quite dif ferent and may not be predicted on the basis of the effectiveness of either therapy alone. We conclude that each of these treatments can be used after failure of the other.
AbstractPrompt, accurate diagnosis of gamma globulin deficiency as a cause of unusual susceptibility to infection is extremely important for several reasons: first, replacement therapy with pooled normal gamma globulin is effective in the prevention of serious infections if initiated before structural damage has occurred; second, supplies of gamma globulin should not be wasted on patients whose susceptibility to infections is due to other causes; and third, patients should not be subjected to the discomfort and possible hazards of repeated large intramuscular injections of gamma globulin except upon clear-cut indications. Significant hypogammaglobulinemia occurs in 3 main forms: (1) in a<i>transient</i>form, as a prolongation of the normally occurring depression of gamma globulin levels between the second and fourth months of infancy; (2) in a<i>congenital</i>form, usually in boys, with sex-linked recessive inheritance; and (3) in an<i>acquired</i>form in both sexes at any age, either as a "primary" disease
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
